Ready To Welcome To...
Health Care: Drugs
Savient Pharmaceuticals (SVNT: NASDAQ)
$0.56 -0.01 | -1.77%
05/24/13 - 03:59 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 0.56 |
| 52 Week High | 2.95 |
| 52 Week Low | 0.48 |
| Avg. Daily Vol. (Mil) | 0.44 |
| Beta (3 year) | 2.36 |
| Share Related Items | |
| Mkt Cap (Mil) | 41.21 |
| Shares Out (Mil) | 73.61 |
| Float (Mil) | 59.99 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 3.30 |
| Current Ratio | 3.60 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | n.a. |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 2.15 |
| Price/Book | 0.00 |
| Price/Cash Flow | -0.30 |
| Per Share Data | |
| Earnings | -1.52 |
| Sales | 0.26 |
| Book Value | 0.00 |
| Cash Flow | -1.94 |
| Business Summary | |
|---|---|
| Savient Pharmaceuticals, Inc., is a biopharmaceutical company with one meaningful drug, Krystexxa, which treats chronic gout refractory to conventional therapy. | |
| General Information | |
| 00 Crossing Boulevard
3rd Floor Bridgewater, NJ 08807 |
|
| www.savientpharma.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 122 | |
| CEO: Mr. Louis Ferrari | |
| Short Interest | |
| Current Month (Mil) | 15.95 |
| Previous Month (Mil) | 16.50 |
| Short Interest Ratio (Days) | 69.00 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -176.70 |
| Return on Investments | -244.00 |
| Profitability | |
| Gross Margin | 57.60 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with SVNT
- Portfolio NameUser Type
- Usertest1123
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Setting Up...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorBreakout Stocks Of The Week...
- Contributor10 Stocks That Could Rise i...
- Contributor13 Biotech Stocks Bought an...
- Contributor10 Most Shorted Stocks in B...
Latest SVNT Headlines from TheStreet
- SVNT July Options Begin Trading 05.20.13 | 02:05 pm
- Arena Pharmaceuticals And 6 More Stocks To Watch 01.07.13 | 07:01 pm
- Lessons From Biotech's Best Third Quarter Stocks 10.02.12 | 09:10 am
- Savient Bulls Come Back for More 09.19.12 | 05:09 am
- 5 Stocks Under $10 Set to Soar 08.16.12 | 01:08 pm
- 5 Stocks Poised for Breakouts 08.10.12 | 01:08 pm
- Savient Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript 08.08.12 | 01:08 pm
- Juicy Details From Tang Capital's Lawsuit Against Savient Pharma 05.01.12 | 03:05 pm
- Biotech Stock Mailbag: Amarin 04.23.12 | 07:04 am
- 10 Stocks That Could Rise in Market Decline 04.10.12 | 07:04 am
Press Releases for SVNT
- Savient's KRYSTEXXA® (pegloticase) Receives European Commission Marketing Authorization For The Treatment Of Certain Patients With Chronic Tophaceous Gout - PR Newswire 01.08.13 | 11:01 am
- Savient Pharmaceuticals To Present At The 31st Annual J.P. Morgan Healthcare Conference - PR Newswire 01.04.13 | 08:01 am
- Savient Receives Positive CHMP Opinion For KRYSTEXXA® Approval In The EU - PR Newswire 10.19.12 | 10:10 am
- Savient Pharmaceuticals Names John P. Hamill Chief Financial Officer - PR Newswire 09.24.12 | 07:09 am
- Analysis Of KRYSTEXXA® Phase III Data Demonstrates Improved Health-Related Quality Of Life And Physical Function In Refractory Chronic Gout Patients - PR Newswire 07.02.12 | 08:07 am
- Savient Pharmaceuticals Completes Financing And Debt Restructuring Transactions - PR Newswire 05.09.12 | 03:05 pm
- Savient Pharmaceuticals And Jim Belushi Launch "Check Out Your Gout" Educational Campaign - PR Newswire 11.07.11 | 08:11 am
- Savient Pharmaceuticals Announces Publication Of Pivotal Phase III KRYSTEXXA® Data In JAMA Demonstrating Significant Benefits In Refractory Chronic Gout Patients - PR Newswire 08.16.11 | 04:08 pm
- Savient Pharmaceuticals To Present At The Wedbush Securities 2011 Life Sciences Management Access Conference - PR Newswire 08.10.11 | 04:08 pm
- Savient Pharmaceuticals To Hold Second Quarter 2011 Financial Results Conference Call On Thursday, August 4, 2011 - PR Newswire 07.20.11 | 04:07 pm
Partner Headlines for SVNT
- Perrigo expands UK presence - Financial Times 02.11.13 | 05:02 pm
- OCZ Tech: Untouchable For Now - Seeking Alpha 10.11.12 | 09:10 am
- 3 High Beta Liquid Small-Cap Biotechnology Stocks That Are Breaking Out - Seeking Alpha 09.17.12 | 09:09 am
- 5 Pharmaceutical Companies With EMA Or MHRA Catalysts This Year - Seeking Alpha 08.28.12 | 09:08 am
- Benzinga's Microcap Movers for Friday August 24, 2012 - Benzinga 08.26.12 | 09:08 am
- Healthcare Business Review: Savient's Favorable RULING, Forest Gets FDA OKAY - Wall St. Cheat Sheet 07.24.12 | 08:07 am
- Savient Gets New CEO, Cuts Jobs - Analyst Blog - Zacks 07.10.12 | 07:07 pm
- Savient Pharmaceuticals Note Holders Claim Default -8K - Benzinga 06.09.12 | 08:06 am
- 2 Biotech Stocks To Consider Now, 1 To Avoid - Seeking Alpha 04.10.12 | 09:04 am
- VIX - Options Volatility Sonar: Friday Recap - Seeking Alpha 03.16.12 | 05:03 pm
